"LONDON, UK â€” The European Commission (EC) has followed the recommendation last year from its Committee for Medicinal Products for Human Use (CHMP) for an additional indication for the oral platelet inhibitor ticagrelor (Brilique, AstraZe"...
Overdosage of Neostigmine Methylsulfate (neostigmine methylsulfate (neostigmine methylsulfate injection) injection) can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. Myasthenic crisis, due to an increase in the severity of the disease, is also accompanied by extreme muscle weakness and may be difficult to distinguish from cholinergic crisis on a symptomatic basis. However, such differentiation is extremely important because increases in the dose of Neostigmine Methylsulfate (neostigmine methylsulfate (neostigmine methylsulfate injection) injection) or other drugs in this class, in the presence of cholinergic crisis or of a refractory or "insensitive" state, could have grave consequences.The two types of crises may be differentiated by the use of edrophonium chlorideŠas well as by clinical judgement.
Treatment of the two conditions differs radically.Whereas the presence of myasthenic crisis requires more intensive anticholinesterase therapy, cholinergic crisis calls for the prompt withdrawal of all drugs of this type.The immediate use of Atropine in cholinergic crisis is also recommended.
Atropine may also be used to abolish or minimize gastrointestinal side effects or other muscarinic reactions;but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.
The LD50 of Neostigmine Methylsulfate (neostigmine methylsulfate (neostigmine methylsulfate injection) injection) in mice is 0.3 ± 0.02 mg/kg intravenously, 0.54 ± 0.03 mg/kg subcutaneously and 0.395 ± 0.025 mg/kg intramuscularly; in rats the LD50 is 0.315 ± 0.019 mg/kg intravenously, 0.445 ± 0.032 mg/kg subcutaneously and 0.423 ± 0.032 mg/kg intramuscularly.
Neostigmine Methylsulfate (neostigmine methylsulfate (neostigmine methylsulfate injection) injection) Injection, USP is contraindicated in patients with known hypersensitivity to the drug. It is also contraindicated in patients with peritonitis or mechanical obstruction of the intestinal or urinary tract.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/26/2008
Additional Neostigmine Methylsulfate Information
- Neostigmine Methylsulfate Drug Interactions Center: neostigmine methylsulfate inj
- Neostigmine Methylsulfate Side Effects Center
- Neostigmine Methylsulfate FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.